FDA Approved: FIASP — Supplemental Application (Novo Nordisk)

View source ↗

Summary

FDA approved a supplemental application for FIASP (insulin aspart injection) by Novo Nordisk. The approval results in an updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Fiasp (insulin aspart)

Snippet

SUPPL AP for FIASP (INSULIN ASPART INJECTION)